All News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
28.97 ^USD	-8.06%		-13.03%	-10.81%

Jun. 14	Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...
Jun. 14	Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...	Jun. 14
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	Jun. 14	MT
Teva sues Corcept over mifepristone 'monopoly' for rare disorder	Jun. 13	RE
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer	Jun. 06	AQ
Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating	Jun. 04	MT
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)	Jun. 03	GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with Hypercortisolism	May. 29	AQ
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	May. 28	MT
Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance	May. 28	MT
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)	May. 28	GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)	May. 28	AQ
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing?S Syndrome)	May. 28	CI
Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing	May. 16	MT
Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	May. 02	MT
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22	May. 01	MT
Transcript : Corcept Therapeutics Incorporated, Q1 2024 Earnings Call, May 01, 2024	May. 01
Corcept: Q1 Earnings Snapshot	May. 01	AQ
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	GL
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

All News

Filters